Background {#Sec1}
==========

Sickle cell disease (SCD) is one of the most common genetic diseases in the world, with the highest prevalence in sub-Saharan Africa, the Caribbean, the Middle East and India \[[@CR1]\]. The morbidity and mortality from Sickle Cell Anaemia (SCA) in developed countries has improved significantly over the last five decades, with studies showing median survival rates beyond the fifth decade of life \[[@CR2]\]. In developing countries, however, SCA still causes significant morbidity and mortality with the greatest burden of the disease in sub-Saharan Africa. The World Health Organization (WHO) estimates over half of children born with SCA in sub-Saharan Africa will die before they reach adulthood \[[@CR3]\]. Infectious diseases, such as malaria and pneumococcal disease (meningitis, pneumonia, and septicaemia) are thought to be the major cause of morbidity and mortality \[[@CR4], [@CR5]\].

Tanzania ranks fifth in the world for number of SCD births with an estimated prevalence of 6 \[interquartile range (IQR) 1--13\] per 1000 births, equivalent to 11,000 SCD births per year \[[@CR4], [@CR6]\]. A study conducted at a university teaching hospital in Tanzania reported a SCA mortality rate of 1.9 per 100 person years of observation (PYO), with the highest incidence of death occurring in the first five years of life \[[@CR7]\]. Overall median survival in this study was 33 years. Of note, life expectancy of Tanzanian residents is 52 years. Similar to other developing countries, morbidity and mortality due to SCA in Tanzania is highly influenced by comorbid conditions, such as infections (particularly malaria), anaemia, and poor nutrition \[[@CR4]\].

Emergency department (ED) presentations of SCA complications are well characterized in developed countries, with the majority of these patients presenting with pain crisis \[[@CR8]--[@CR12]\]. Most of these patients are treated with aggressive pain management and fluid therapy and discharged home, with less than one-third admitted to the hospital. In 2010, Muhimbili National Hospital (MNH), which is the main University Teaching Hospital, opened the first full capacity, high-volume ED in Tanzania. This ED has provided an opportunity for early stabilization and resuscitation of acutely ill patients, including those with SCA. The study on mortality in SCA in Africa published in 2011 was conducted at the same hospital, at that time had no full capacity ED \[[@CR7]\]. This is critical as little is known about the acute or emergent manifestations, management, and outcomes of SCA complications in Tanzania. The primary aim of this investigation is to describe the clinical presentation, ED management, and hospital outcomes of individuals known or suspected to have sickle cell disease and presenting to the MNH ED.

Methods {#Sec2}
=======

Study design and setting {#Sec3}
------------------------

This was a prospective observational study of consecutive patients presenting to the MNH ED in Dar es Salaam, Tanzania, from 1 December 2014 to 31 July 2015. MNH has a bed capacity of 1500 and serves as the top referral hospital in Tanzania. The ED was established in 2010 via a partnership between the Ministry of Health and Social Welfare, and Abbott Fund Tanzania. The ED is the first full capacity public ED in Tanzania, and the training site for the only emergency medicine (EM) residency program in the country. The department is staffed 24 h, seven days a week by locally trained specialist emergency physicians, who oversee the care of patients and training of interns, registrars, and EM residents. The ED sees an average of 45,000 patients annually, with an admission rate of around 65%. The top disease categories in all age groups are trauma, infectious disease, and mental health \[[@CR13]\]. MNH is one of the largest SCD treatment and research centre in Tanzania. The diagnosis of SCA at MNH is normally confirmed by the haemoglobin electrophoresis, after initial sickling test or clinical suspicion at most of the referring hospitals. Patients confirmed to have SCA are enrolled into a Sickle Cell clinic, provided with dedicated medical record number and special follow up card. In this study, all patients with confirmed evidence of SCA presenting with acute illness at the ED were eligible for enrolment.

Study protocol {#Sec4}
--------------

Screening and enrolment was completed by a research assistant and the study investigator (HS). A structured data sheet was used to record study information, including demographics, pre-referral information, chief complaints, initial vital signs, history and physical examination findings, laboratory results, treatment delivered, and final ED diagnoses and disposition. All diagnostic, treatment, and disposition decisions were made at the discretion of the treating physician. The research assistant followed up on all enrolled patients throughout the duration of their hospital study and recorded lengths of stay in hospital and intensive care unit (ICU) or high acuity ward, as well as final hospital diagnosis and clinical outcome (discharge or death) for each patient.

Data analysis {#Sec5}
-------------

Information collected from the handwritten data sheets were transferred into an Excel spreadsheet (Microsoft Corporation, Redmond, WA, USA), verified, and checked for any errors and outliers. Data were subsequently imported into StatsDirect (version 3.0.167, StatsDirect Ltd., Cheshire, UK) for analysis. Categorical variables were summarized as frequencies and percentages, and continuous variables as means and standard deviations (SD) or medians and interquartile ranges (IQR), depending on data distribution. Normality was assessed using the Shapiro-Wilk test. Ninety-five percent confidence intervals (CI) are presented where appropriate, and were calculated by the Clopper-Pearson (exact) method. Categorical variables were compared with chi-square test or Fisher's exact test; continuous variables were compared with two-sample t-test or Mann-Whitney U-test. Two-tailed *p*-values of \< 0.05 were considered statistically significant.

Results {#Sec6}
=======

We enrolled 752 (2.7%) people with SCA from 28,322 patients who presented to the MNH ED from 1 December 2014 to 31 July 2015. The median age of enrolled patients was 14 years (Interquartile range (IQR) of 6--23 years), with 19.7% younger than age 5, and 52.9% were female. A total of 299 (40.2%) patients were referred from peripheral hospitals, the median length of admission at these peripheral facilities prior to referral was 2 days (IQR 1.3 days) Table [1](#Tab1){ref-type="table"}.Table 1Patient demographicsDemographicsNumberPercentage (%)Sex*N* = 747 Female39552.9 Male35247.1Age Group*N* = 741 1 month--\< 5 years14619.7 5 years--\< 18 years30441.0 ≥ 18 years29139.3Referral Status*N* = 744 Self referral44559.8 Referred29940.2

Patients' baseline variables and presenting complaints {#Sec7}
------------------------------------------------------

Tachypnea 336 (44.7%) was the most frequent abnormal vital sign among enrolled patients, while bradycardia 14 (1.9%) was the least frequent abnormal sign. All the abnormality are based on age-appropriate vital signs \[[@CR14]\]. Patients who presented fever 289 (17.4%), hypoxia 67 (8.9%), altered mental status 59 (7.8%) and bradycardia 14 (1.9%) had a statistically significant higher relative risk of death compared with those without bradycardia. Pain 614 (81.6%) and urinary symptoms 6 (0.8%) were most and least frequent presenting complaints respectively Table [2](#Tab2){ref-type="table"}.Table 2Patients' baseline variables and presenting complaintsOverallDiedSurvivedRelative risk*P*-value*N* = 752*N* = 16*N* = 736Clinical characteristicsn (%)n (%)n (%)RR (95%CI)Tachypnea ^b^336 (44.7)10 (62.5)326 (44.3)2.1 (0.8--5.7)0.16Tachycardia^b^186 (24.7)5 (31.3)181 (24.6)1.4 (0.5--3.9)0.5Febrile (*T* \> 37.5 °C)^c^131 (17.4)11 (68.8)120 (16.3)10.4 (3.7--29.5)\< 0.0001SpO~2~^a^ \< 95%67 (8.9)15 (93.8)52 (7.1)153 (20--1143)\< 0.0001Altered mental status59 (7.8)13 (81.3)46 (6.3)50 (15--174)\< 0.0001Bradycardia^b^14 (1.9)3 (18.8)11 (1.5)12.1 (3.9--38.0)\< 0.0001Pain614 (81.6)12 (75.0)602 (81.8)0.7 (0.2--2.1)0.5Fever289 (38.4)10 (62.5)279 (37.9)2.7 (1.0--7.3)0.06Abdominal Symptoms159 (21.1)2 (12.5)157 (21.3)0.5 (0.1--2.3)0.4Respiratory Symptoms156 (20.7)11 (68.8)145 (19.7)8.4 (3.0--23.8)0.0001Cardiovascular Symptoms83 (11.0)2 (12.5)81 (11.0)1.2 (0.3--5.0)0.9Jaundice80 (10.6)1 (6.3)79 (10.7)0.6 (0.1--4.2)0.6Body Swelling54 (7.2)2 (12.5)52 (7.1)1.9 (0.4--7.9)0.4Neurological Symptoms45 (6.0)6 (37.5)39 (5.3)9.4 (3.6--24.8)\< 0.0001Long Lasting Erection20 (2.7)1 (6.3)19 (2.6)2.4 (0.3--17.6)0.4Urinary Symptoms6 (0.8)1 (6.3)5 (0.7)8.3 (1.3--53.1)0.03^a^*SpO*~*2*~ Saturation of oxygen in peripheral capillary ^b^Age-adjusted variables ^c^ Measurements were all axillary

Investigations ordered in the ED {#Sec8}
--------------------------------

Nearly all patients 744 (99%) had at least one laboratory test done while receiving ED care. Complete blood cell counts were ordered for 656 (87.2%) patients. Of these 346 (52.7%) had elevated white blood counts (\> 11 K/uL) and 342 (52.1%) had severe anaemia (Hb \< 7 g/dL) of which 166 (25.3%) had (Hb \< 5 g/dL). Of the 415 patients tested for malaria, 48 (11.6%) were positive. The relative risk of death among those with severe anaemia, malaria test positive, elevated renal function test and hypoglycaemia was 30.3, 22.9,10.4 and 45.2 respectively. X-ray of the chest was ordered in 85 (11.3%) of patients, and the relative risk of death among those with an abnormal chest x-ray was 4.0 (Table [3](#Tab3){ref-type="table"}).Table 3Investigations ordered in the EDOverallDiedSurvivedRelative risk*P*-valuen/N (%)n/N (%)n/N (%)RR (95%CI)Laboratory Tests WBC ^**Ω**^ (\> 11 K/uL)346/656 (52.7)11/16 (68.8)335/640 (52.3)2.0 (0.7--5.6)0.2 Haemoglobin (\< 7 g/dL)342/656 (52.1)16/16 (100)326/640 (50.9)30.3 (1.8--503)0.02 Abnormal urine results ^**δ**^11/63 (17.5)1/16 (6.3)10/47 (21.3)0.3 (0.04--2.11)0.2 Malaria test positive48/415 (11.6)12/16 (75)36/399 (9.0)22.9 (7.7--68)\< 0.0001 Elevated RFT^**β**^24/219 (11.0)9/16 (56.3)15/203 (7.4)10.4 (4.2--25.5)\< 0.0001 Low RBG^**η**^ (\< 3 mmol/L)39/627 (6.2)12/16 (75)27/611 (4.4)45.2 (15.3--133.8)\< 0.0001Imaging Tests Abnormal chest x-ray ^**α**^30/85 (35.3)11/16 (68.8)19/69 (27.5)4.0 (1.5--10.5)0.004 Abnormal brain CT scan ^**ρ**^7/26 (26.9)5/16 (31.3)2/10 (20)1.2 (0.67--2.2)0.5^Ω^ WBC-White Blood Cell^δ^ Presence of blood in urine, leukocytes, nitrites, albumin, or glucose^α^ Signs of infection or stroke^β^ RFT-Renal function test^η^ RBG-Random Blood Glucose^α^ Pneumonic changes^ρ^ Signs of stroke

Final ED diagnosis {#Sec9}
------------------

The top three ED diagnoses were painful crisis (*n* = 472; 62.8%), malaria (*n* = 176; 23.4%), and severe anaemia (*n* = 117; 15.6%) (Table [4](#Tab4){ref-type="table"}).Table 4Final ED diagnosisFinal ED Diagnosis*N* = 752% (95% CI)Painful crisis47262.8 (59.3--66.2)Malaria17623.4 (20.5--26.6)Severe anaemia11715.6 (13.2--18.3)Pneumonia10514.0 (11.7--16.6)Acute chest syndrome496.5 (5.0--8.5)Hypoglycaemia425.6 (4.2--7.5)Urinary tract infection415.5 (4.0--7.3)Acute kidney injury273.6 (2.5--5.2)Priapism182.4 (1.5--3.8)Cerebral vascular accident162.1 (1.3--3.4)

ED treatment and interventions {#Sec10}
------------------------------

In the ED, intravenous fluid bolus and intravenous dextrose were given to 370 (49.2%) and 129 (17.2%) of enrolled patients, respectively. A total of 489 patients (65.0%) received analgesics for pain, with 350 (71.6%) receiving opioid analgesics. Antimalarial were administered in the ED to 123 (16.4%) patients, while 220 (29.3%) received antibiotics, the majority of whom (89.2%) received intravenous ceftriaxone. Seventy-two patients (9.6%) received blood products (fresh whole blood, packed red cells, or fresh frozen plasma), with the majority (91.2%) receiving fresh whole blood.

Patients' disposition and hospital outcomes {#Sec11}
-------------------------------------------

Of the 752 SCA patients seen in the ED, 534 (71%) were hospitalized for inpatient care, while five patients (0.7%) died in the ED. The median length of stay in hospital was 3 days (Interquartile range (IQR): 1--5) days. The overall morality (ED plus inpatient) was 16 (2.1%). Overall, 8 (50%) of deaths' occurred within 24 h of ED presentation (Table [5](#Tab5){ref-type="table"}).Table 5Patients' disposition and hospital outcomesDisposition*N* = 752% (95% CI)Admitted53471.0 (67.6--74.2)Discharged from ED21328.3 (25.1--31.7)Died in ED50.7 (0.3--1.5)Death within 24-h of ED presentation ^ϖ^81.1 (0.5--2.1)Inpatient mortality ^φ^112.1 (1.2--3.7)Overall mortality162.1 (1.3--3.4)MedianIQRMedian length of hospital stay3 days1--5 daysϖ Includes ED and inpatient deathsφ Includes only in patients' deaths (denominator: *N* = 534) those who were admitted

Discussion {#Sec12}
==========

The opening of a full capacity ED at MNH provided a unique opportunity for rapid assessment and early stabilization of acutely ill individuals, including those with SCA. Our study reports on the clinical profile and management of acutely ill individuals with SCA presenting to an urban ED in Tanzania. This information on ED access and resource utilization can be useful in developing local and countrywide strategies to improve access, treatment guidelines, and health outcomes among individuals with SCA.

In our study, the prevalence of SCA among acutely ill patients presenting ED was found to be 2.7%, and most of the patients were self-referral, highlighting the role of ED as a major mode of healthcare utilization in this patient population in Tanzania. Most of our patients were children below eighteen years, an observation consistent with previously published literature in the same settings \[[@CR7]\].

Pain was the most common presenting complaints among patients presenting to ED. Vaso-occlusive painful crisis phenomena is a well documented reason for ED visit among sickle cell patients in different settings \[[@CR7], [@CR8]\], and it has been shown to be a potential marker of serious illness, which may be associated with increased morbidity and mortality \[[@CR7], [@CR15]\]. Respiratory compromise, denoted by tachypnea and hypoxia (oxygen saturation \< 95%), was the most common physical examination finding at presentation. In this population, the most common reason for respiratory compromise was chest infection (pneumonia), followed by acute chest syndrome. Infection is the leading cause of preventable morbidity and mortality in patients with SCA, and previous studies reported mortality as high as 38% in the USA, in absence of aggressive treatment \[[@CR16], [@CR17]\]. Standardized treatment and prevention (i.e. prophylactic penicillin and vaccination against pneumococcal infections) have significantly improved the outcome and quality of life \[[@CR18]\]; however, these interventions are not routinely available to our patient population as they are not part of standard care \[[@CR19]\]. When present, bradycardia, altered mental status, and hypoxia were each associated with a relative risk of death of greater than 10 in our study population compared to when these features were absent.

In addition to physical examinations, most of these patients received laboratory and imaging tests. More than three-quarters of patients had a complete blood cell count as part of their ED care, more than half of who had severe anaemia. All patients who died had severe anaemia at presentation. Severe anaemia was associated with a significantly higher relative risk of death when compared with higher haemoglobin levels. These findings are similar to previous literature in similar settings, which have shown low haemoglobin to be an independent predictor of mortality in patients with SCA \[[@CR16], [@CR20]\]. Severe anaemia is reported to negatively impact outcome and quality of life in SCA patients \[[@CR20]\]. In our patient cohort, only 21% of patients with severe anaemia received blood transfusion in the ED. The current local guideline for management of severe anaemia in patients with SCA recommends blood transfusion to all SCA patients with haemoglobin (Hb) less than 5 g/dL, regardless of presenting complaint, and to those with Hb \< 7 g/dL if symptomatic \[[@CR21]\]. In this study population, 25.3% of patients had haemoglobin less than 5 g/dL, but overall more than half of patients who should receive blood products as part of their ED care did not receive it. Several factors may impact availability, access, and transfusion practices in our ED, including lack of enough eligible donors, lack of testing and storage equipment, lack of recognition and late presentation \[[@CR22], [@CR23]\]. We are unable to determine the exact reasons for the low rate of transfusion in our study. Thus, we recommend further study to address what appears to be a significant opportunity for improvement in emergency care of acute SCA cases. The findings of hypoglycaemia, positive malaria test, abnormal renal function tests and abnormal chest x-ray findings were all associated with a significantly higher relative risk of death compared to patients with normal results. All of these abnormal findings are easily manageable at MNH, and at most of the basic facilities within Tanzania, hence further studies should focus on addressing the challenges associated with care and factors associated with mortality within these conditions so as to ensure death from these conditions are prevented.

Painful crisis, malaria and severe anaemia were the top three ED providers' diagnosis. Malaria was diagnosed in 176 patients by ED providers, while only 48 of patients tested positive, this might indicate an over diagnosis by ED providers, however we were unable to detect whether the providers used syndrome approach to treatment of malaria which calls for use of antimalarial for suspicious cases regardless of the malaria test results \[[@CR24]\].

Over two-thirds of patients were admitted for inpatient care after initial stabilization in the ED. This is a much higher admission rate than reported in many developed countries \[[@CR8], [@CR10], [@CR12]\], but similar to the overall ED disposition patterns in our setting \[[@CR13]\]. The overall mortality in our study population was 2.1%, with 50% of the deaths occurring within the first 24 h of presentation to the ED. Our results show that severe anaemia, infection (malaria and bacterial infection), and hypoxia are associated with increase in mortality in our study population. These contributors should receive focused attention in the design of ED care protocols for SCA and further studies.

Limitations {#Sec13}
-----------

The generalizability of our results may be limited due to the single-centre nature of our study. The ED at MNH is the entry point to the largest tertiary referral hospital in Tanzania, and receives acutely ill patients from all over the country. Therefore, the sample seen at the MNH ED might be different than that seen at the district hospitals and health centres. The exclusion of undiagnosed SCD in our study might have under-estimated the overall proportion of SCD in our study population. In addition, the assessment of factors associated with mortality was limited by the number of deaths in our study population.

Conclusions {#Sec14}
===========

We have provided a description of the clinical presentation, management, and outcomes of patients with SCA presenting to the largest public emergency department in a tertiary referral hospital in Tanzania. These data will inform development of strategies to provide education for clinical staff, treatment guidelines, and clinical research aimed at optimizing care of the SCA patient population.
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